Roche CMO Sandra Horning speaks at an Endpoints News breakfast, January 2019 [Jeff Rumans for Endpoints News]
September 12, 2019 06:46 AM EDTUpdated 06:59 AM
R&D
Pharma

Look out Alex­ion, Roche breaks out the de­tails on its ri­val rare CNS drug

Natalie Grover

Reporter

Months af­ter Alex­ion scored the first-ever ap­proval for pa­tients with neu­romyelitis op­ti­ca spec­trum dis­or­der (NM­SOD) — re­searchers at Roche have come out with de­tailed da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times